Lung Cancer Europe shared a post on X:
“Where you live in Europe determines your access to lung cancer treatment.
This week, EFPIA published its W.A.I.T. Indicator 2025, tracking how quickly medicines approved by the European Medicines Agency reach patients across EU member states.
~ 1/2 of all approved medicines are not available to patients in Europe. For oncology medicines, the average wait has increased year on year. These delays have real consequences. Lung cancer treatment is evolving rapidly – time is rarely on a patient’s side.
Policymakers and health systems across Europe must treat equitable access as a priority, not an aspiration.”
Other articles about Lung Cancer Europe on OncoDaily.